| Title: | Designing a Screening Program for Nonalcoholic Fatty Liver Disease in the Primary Care Population |
| Lead Institution: | Washington University in St. Louis |
| Principal investigator: | Dr Scott McHenry |
Application 50689
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
About
Nonalcoholic fatty liver disease is the liver-complication of obesity. It is the fastest growing cause of liver cirrhosis and liver cancer. It is also strongly associated with heart disease and diabetes mellitus, where a fatty liver often can be found years before those conditions are present. If a fatty liver can be reversed by diet, exercise or medications, it is likely that we can prevent these complications. Unfortunately, it is not as simple as imaging everybody since these tests (CAT scans, ultrasounds) are not very good at picking up subtle degrees of liver fat that still predispose to these conditions. We have developed a risk-score based on routinely obtained blood work for nonalcoholic fatty liver disease to identify patients at an early stage before they develop complications such as diabetes mellitus or liver cirrhosis. Before this can be used in primary care clinics, we must confirm that it is predictive in more than one country, which is why we wish to validate the score in the UK biobank.1 Publication
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 5978 | Validation of the Dallas Steatosis Index to Predict Nonalcoholic Fatty Liver Disease in the UK Biobank Population | Scott McHenry (+2) | 2021 | Clinical Gastroenterology and Hepatology |
Enabling scientific discoveries that improve human health